WNK2 and neoplasm: Sorafenib is a multi-kinase inhibitor that interferes with intracellular and extracellular signalling pathways associated with tumour angiogenesis and tumour proliferation, including vascular endothelial growth factor receptors, platelet-derived growth factor receptor and RAF/mitogen-activated protein kinase.3 The SHARP and Asia-Pacific studies confirmed overall survival (OS) benefit of sorafenib over placebo; however, the median age of patients in both studies was <65 years.4,5